# Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

> **NCT02053311** · PHASE3 · WITHDRAWN · sponsor: **Swiss Cancer Institute**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Orteronel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02053311
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-08-19
- **Primary completion:** 2014-08-19
- **Final completion:** 2034-08-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to former trials, drug has not demonstrated a clinical profile sufficient to move forward in mCRPC
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02053311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02053311, "Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02053311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*